Overview


According to FutureWise analysis the market for Nonalcoholic Steatohepatitis (NASH) in 2023 is US$ 2.02 billion, and is expected to reach US$ 28.86 billion by 2031 at a CAGR of 39.40%.

FutureWise Market Research has illustrated a report on the Nonalcoholic Steatohepatitis (NASH) Market. The report provides an in-depth anatomy of market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The Nonalcoholic Steatohepatitis (NASH) Market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Genfit
  • Intercept Pharmaceuticals
  • Gilead Sciences
  • Tobira Therapeutics
  • Galmed Pharmaceuticals
  • Bristol-Myers Squibb
  • Cirius Therapeutics
  • Conatus Pharmaceuticals
  • Allergan
  • Inventiva

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Disease Cause

  • Hypertension
  • Heart Disease
  • High Blood Lipid
  • Type 2 Diabetes
  • Obesity

By Drug Type

  • Vitamin E and Pioglitazone
  • Ocaliva
  • Elafibranor
  • Selonsertib
  • Cenicriviroc
  • Others

By End User

  • Hospitals
  • Clinics
  • Homecare settings

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Nonalcoholic Steatohepatitis (NASH) Market by disease cause, by drug type, by end user and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industryspecific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and the Middle East and Africa
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Nonalcoholic Steatohepatitis (NASH) Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Nonalcoholic Steatohepatitis (NASH) Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Nonalcoholic Steatohepatitis (NASH) Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Nonalcoholic Steatohepatitis (NASH) Market, By Disease Cause Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Hypertension
        2. Heart Disease
        3. High Blood Lipid
        4. Type 2 Diabetes
        5. Obesity

  • 8.   Nonalcoholic Steatohepatitis (NASH) Market, By Drug Type Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Vitamin E and Pioglitazone
        2. Ocaliva
        3. Elafibranor
        4. Selonsertib
        5. Cenicriviroc
        6. Others

  • 9.   Nonalcoholic Steatohepatitis (NASH) Market, By End User Historical Analysis and Forecast 2025-2033 (USD Million)

    •   1. Hospitals
        2. Clinics
        3. Homecare settings

  • 10.   North America Nonalcoholic Steatohepatitis (NASH) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2025-2033

  • 11.   Latin America Nonalcoholic Steatohepatitis (NASH) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2025-2033

  • 12.   Europe Nonalcoholic Steatohepatitis (NASH) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2025-2033

  • 13.   Asia Pacific Nonalcoholic Steatohepatitis (NASH) Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2025-2033

  • 14.   Middle East and Africa Market Analysis 2018-2024 and Forecast 2025-2033 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2024
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2025-2033

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •   1. Genfit
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Intercept Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Gilead Sciences
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Tobira Therapeutics
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Galmed Pharmaceuticals
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Bristol-Myers Squibb
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Cirius Therapeutics
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Conatus Pharmaceuticals
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Allergan
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Inventiva
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 113 519 7222
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11